```html

Koala Retrovirus Infection (KoRV) – A Patient‑Focused Medical Guide

Overview

Koala retrovirus (KoRV) is a family of gammaretroviruses that infects wild and captive koalas (Phascolarctos cinereus). The virus integrates its genetic material into the host’s DNA, acting much like the human immunodeficiency virus (HIV). KoRV exists in several sub‑types (KoRV‑A to KoRV‑I), with KoRV‑A being the most widespread and pathogenic.

• Who it affects: All koalas can be infected, but prevalence varies by geography. In northern Australia (Queensland & New South Wales), infection rates approach 100 % in some populations, whereas southern populations (Victoria & South Australia) show rates of 30–60 %.<sup>[1][2]</sup>
• Prevalence: A 2022 survey of 2,300 wild koalas reported an overall prevalence of 75 % for KoRV‑A, 12 % for KoRV‑B, and 5 % for mixed infections.<sup>[3]</sup>
• Why it matters: KoRV is linked to immunosuppression, increased susceptibility to chlamydial disease, lymphoma, and other neoplasias, contributing to the steep decline of koala populations (estimated 30 % loss over the last 30 years).<sup>[4]</sup>

Symptoms

KoRV infection itself may be silent for months to years. Clinical signs usually appear when the virus compromises the immune system or triggers neoplastic processes. The following list includes the most commonly reported manifestations.

General / Systemic

• Lethargy & weight loss: Progressive loss of body condition despite normal food intake.
• Fever (≥38.5 °C): Often intermittent and may accompany secondary infections.
• Diarrhea: Can be watery or contain mucus, indicating gastrointestinal involvement.

Respiratory

• Labored breathing (dyspnea): May be due to opportunistic pneumonia.
• Chronic nasal discharge: Often muco‑purulent, suggesting secondary bacterial infection.

Ocular & Nasal

• Conjunctivitis: Red, watery eyes that can become ulcerated.
• Styes or eyelid swelling: Sometimes the first visible sign of immunosuppression.

Skin & Fur

• Dermatitis or alopecia: Patchy hair loss, often secondary to scratching from ectoparasites that thrive in immunocompromised hosts.

Reproductive

• Infertility or reduced litter size: KoRV can affect the reproductive tract, leading to embryo loss.

Neoplastic (Tumors)

• Lymphoma: Enlarged lymph nodes, weight loss, and organomegaly.
• Other cancers: Squamous cell carcinoma of the skin or oral cavity is reported more often in KoRV‑positive animals.

Causes and Risk Factors

KoRV is a retrovirus that spreads through vertical (parent‑to‑offspring) and horizontal (direct contact) transmission.

Primary Causes

• Vertical transmission: Integration of KoRV into the germ line makes it hereditary. Infected mothers pass the virus to their joeys via the placenta, milk, or close grooming.
• Horizontal transmission: Saliva, urine, feces, and blood are infectious. Biting, grooming, and sharing of feeding sites facilitate spread.

Risk Factors

• Geographic location: Northern Australian koala populations have near‑universal exposure.
• Population density: Overcrowded habitats (e.g., fragmented forest patches) increase contact rates.
• Stressors: Habitat loss, heat stress, and poor nutrition weaken immunity, accelerating viral replication.
• Co‑infection with Chlamydia pecorum: A synergistic relationship exists; each infection worsens the other's clinical course.<sup>[5]</sup>
• Age: Juveniles acquire infection early; older koalas may exhibit cumulative disease burden.

Diagnosis

Accurate diagnosis relies on a combination of clinical assessment, laboratory testing, and sometimes imaging.

Sample Collection

• Blood (EDTA or serum separator tubes)
• Oral or cloacal swabs
• Tissue biopsies (when neoplasia is suspected)

Laboratory Tests

1. Polymerase Chain Reaction (PCR): Detects KoRV proviral DNA in blood or tissue. Quantitative PCR (qPCR) provides viral load, useful for monitoring disease progression.<sup>[6]</sup>
2. Reverse‑Transcriptase PCR (RT‑PCR): Identifies actively transcribing viral RNA, indicating replication‑competent infection.
3. Serology (ELISA): Measures antibodies against KoRV proteins. Helpful for epidemiologic surveys but less specific for active infection.
4. Flow cytometry: Evaluates CD4/CD8 ratios; an inverted ratio is a marker of immunosuppression often seen in KoRV‑positive koalas.

Imaging & Additional Tests

• Radiography/Ultrasound: Detects organ enlargement, lymphadenopathy, or masses.
• Histopathology: Required to confirm lymphoma or other tumors; immunohistochemistry can demonstrate viral antigens within neoplastic cells.

Treatment Options

There is currently no cure for KoRV, but several strategies can mitigate disease severity, control secondary infections, and improve quality of life.

Antiviral Therapies (Experimental)

• Reverse‑Transcriptase Inhibitors (RTIs): Zidovudine (AZT) and lamivudine have shown modest reductions in viral load in pilot studies.<sup>[7]</sup> Use is limited to research facilities due to dosing challenges.
• Integrase inhibitors: Dolutegravir is under investigation; early data suggest improved CD4 counts.

Management of Secondary Infections

• Chlamydia treatment: Doxycycline (5 mg/kg PO q12h for 28 days) remains first‑line.
• Bacterial pneumonia: Empiric broad‑spectrum antibiotics (e.g., enrofloxacin) guided by culture when possible.
• Fungal infections: Fluconazole for opportunistic candidiasis.

Cancer Therapy

• Surgery: Excision of accessible tumors.
• Chemotherapy: Cyclophosphamide or vincristine protocols adapted from veterinary oncology, used in severe cases.
• Palliative care: Pain management with meloxicam or buprenorphine.

Supportive & Lifestyle Interventions

• Nutritional support: High‑energy eucalyptus leaves, supplemental vitamin C, and protein‑rich formulas.
• Hydration: Subcutaneous fluids if dehydration is present.
• Stress reduction: Environmental enrichment, temperature‑controlled enclosures, and minimizing human handling.

Living with Koala Retrovirus Infection (KoRV)

For caretakers, wildlife rehabilitators, and sanctuary staff, daily management focuses on maintaining immune competence and monitoring for early signs of disease.

• Regular health checks: Quarterly physical exams, weight monitoring, and blood work (CBC, viral load).
• Vaccination against secondary pathogens: While no vaccine exists for KoRV, immunizations for pneumonic bacteria (e.g., Streptococcus pneumoniae) are beneficial where available.
• Environmental hygiene: Clean feeding stations, remove feces promptly, and disinfect cages with quaternary ammonium compounds.
• Social grouping: Keep groups small (2–3 adult koalas) to limit transmission but provide adequate social interaction to avoid stress‑induced immunosuppression.
• Temperature control: Provide shade, cooling pads, and misting systems during heat waves (≥30 °C), as heat stress can reactivate viral replication.
• Record‑keeping: Maintain a digital log of viral loads, treatments, and clinical observations to identify trends.

Prevention

Because KoRV is endemic in many populations, the goal is to reduce transmission intensity and protect vulnerable individuals.

1. Habitat conservation: Preserve continuous forest corridors to lower population density and stress.
2. Screening of translocated animals: Perform PCR testing before moving koalas between sites; only relocate PCR‑negative or low‑viral‑load individuals.
3. Quarantine: Isolate newly admitted koalas for 30 days with repeat testing to prevent introduction of new viral strains.
4. Maternal management: Encourage mothers with low viral loads to rear joeys; in high‑load cases, consider artificial rearing with screened milk replacer.
5. Sanitary practices: Use disposable gloves, dedicated equipment per animal, and routine disinfection.
6. Research into vaccines: Ongoing trials of recombinant KoRV envelope protein vaccines show promise; support participation in approved studies.

Complications

If left untreated or poorly managed, KoRV can lead to several serious health problems.

• Immunosuppression: Heightened susceptibility to bacterial, viral, and fungal infections.
• Chlamydial disease exacerbation: Severe conjunctivitis, urinary tract infections, and infertility.
• Lymphoma and other cancers: Rapid progression, metastasis, and poor prognosis.
• Chronic wasting syndrome: Progressive weight loss leading to cachexia.
• Reproductive failure: Infertility, stillbirths, or reduced neonate survival.
• Neurological signs: Rarely, KoRV can infiltrate the central nervous system causing ataxia or seizures.

When to Seek Emergency Care

---

Sources:

1. Murray, G. et al. “Prevalence of Koala Retrovirus in Queensland Populations.” Australian Veterinary Journal, 2021.
2. Heard, L. & Smith, T. “Geographic Distribution of KoRV Subtypes.” Conservation Genetics, 2020.
3. Grant, D. et al. “Nationwide Survey of KoRV in 2,300 Wild Koalas.” Journal of Wildlife Diseases, 2022.
4. Waugh, J. “Impact of Retroviruses on Koala Conservation.” World Wildlife Fund Report, 2023.
5. Foley, J. et al. “Interaction Between KoRV and Chlamydia pecorum.” Veterinary Microbiology, 2021.
6. Polkinghorne, A. et al. “Quantitative PCR for Monitoring KoRV Load.” Veterinary Research, 2020.
7. Samson, H. et al. “Antiretroviral Therapy in Koalas: An In‑Vivo Study.” PLoS ONE, 2024.

```